Preliminary Study 2 to Test the Effects of Ambulatory Voice Biofeedback
| Status: | Recruiting |
|---|---|
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 3/10/2019 |
| Start Date: | June 1, 2018 |
| End Date: | April 30, 2021 |
| Contact: | Robert E Hillman, PhD |
| Email: | hillman.robert@mgh.harvard.edu |
| Phone: | 617-643-2466 |
Preliminary Study 2 to Test the Effects of Ambulatory Voice Biofeedback in Small Groups of Patients With Vocal Hyperfunction
Note that this is the second half of a study under the same IRB and NIH grant. This second
study will enroll patients with nodules and those with muscle tension dysphonia. These two
groups will receive ambulatory voice biofeedback throughout 6 weeks of voice therapy. The
targeted objective voice measure during biofeedback will be individually tailored with the
goal of increased percentage compliance.
study will enroll patients with nodules and those with muscle tension dysphonia. These two
groups will receive ambulatory voice biofeedback throughout 6 weeks of voice therapy. The
targeted objective voice measure during biofeedback will be individually tailored with the
goal of increased percentage compliance.
This second study will use a single subject design to determine if adding ambulatory voice
biofeedback to conventional voice therapy can result in faster carryover (compliance) of new
vocal behaviors established during voice therapy to daily life. Here, ambulatory voice
biofeedback will be based on glottal aerodynamic measures that have subject-specific
sensitivity to vocal hyperfunction. Hypothesis: The first ambulatory voice biofeedback week
will result in higher compliance percentages when compared to baseline and the week prior to
the initiation of biofeedback (when there was voice therapy alone). Days/weeks post-AVB will
be significantly different than baseline (successful carryover).
biofeedback to conventional voice therapy can result in faster carryover (compliance) of new
vocal behaviors established during voice therapy to daily life. Here, ambulatory voice
biofeedback will be based on glottal aerodynamic measures that have subject-specific
sensitivity to vocal hyperfunction. Hypothesis: The first ambulatory voice biofeedback week
will result in higher compliance percentages when compared to baseline and the week prior to
the initiation of biofeedback (when there was voice therapy alone). Days/weeks post-AVB will
be significantly different than baseline (successful carryover).
Inclusion Criteria:
- Patients with vocal fold nodules or muscle tension dysphonia undergoing voice therapy
Exclusion Criteria:
- If a patient's baseline ambulatory monitoring data is not at least 1 standard
deviation away from a normative database in any measure, he/she will be excluded.
Non-English speakers are excluded because prompts on the smartphone app are only
available in English.
We found this trial at
1
site
1 Bowdoin Street
Boston, Massachusetts 02114
Boston, Massachusetts 02114
Phone: 617-643-2466
Click here to add this to my saved trials
